Back to Search
Start Over
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
- Source :
-
JAMA oncology [JAMA Oncol] 2020 Jul 01; Vol. 6 (7), pp. 1122. - Publication Year :
- 2020
Details
- Language :
- English
- ISSN :
- 2374-2445
- Volume :
- 6
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- JAMA oncology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 32463423
- Full Text :
- https://doi.org/10.1001/jamaoncol.2020.1516